|
|
|||||||||||
Department of Psychiatry, University of Cambridge, Cambridge
Medical Research Council National Survey of Health and Development, Department of Epidemiology and Public Health, University College London Medical School, London
Department of Psychiatry, University of Cambridge, Cambridge, UK
Correspondence: Professor Peter B. Jones, Department of Psychiatry, Box 189, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. Tel: +44(0)1223 336 961; fax: +44(0)1223 336968; e-mail: pbj21{at}cam.ac.uk
Funding detailed in Acknowledgements.
|
|
ABSTRACT |
|---|
|
|
|---|
Aims To describe antidepressant, anxiolytic and hypnotic drug use, and associations between such medication use and common mental disorder, over a 22-year period.
Method Questions about psychotropic medication use and symptoms of common mental disorder were asked of more than 3000 members of the 1946 British birth cohort at multiple time points between ages 31 and 53 years.
Results Prevalence of any antidepressant, anxiolytic or hypnotic use increased significantly from 1977 (30.6 per 1000) to 1999 (59.1 per 1000) as the cohort aged. Less than 30% with mental disorder used antidepressants, anxiolytics or hypnotics. Previous use of antidepressant, anxiolytic or hypnotic was a strong predictor of future use during an episode of mental disorder (odds ratios 3.0-8.4); this association became weaker over time.
Conclusions Pharmacotherapy is infrequently used by individuals with common mental disorder in Britain; this has not changed in the past three decades.
|
|
INTRODUCTION |
|---|
|
|
|---|
|
|
METHOD |
|---|
|
|
|---|
Follow-up of those alive and still resident in England, Scotland or Wales has been very successful; more than 80% have been followed throughout the cohort's adult years, excluding those who died, emigrated or have permanently withdrawn from the study (Wadsworth et al, 2003). Analyses show few significant biases between those who remained in the study and those who did not (Wadsworth et al, 1992), and comparisons with census data suggest that the remaining cohort (n=3673 at age 53 years) is broadly representative of all native-born adults of a similar age and currently resident in England, Scotland or Wales (Wadsworth et al, 2003).
Psychiatric treatment
Survey members reported all prescription medication use in a postal
questionnaire at age 31 years, and in person to a nurse interviewer at ages
36, 43 and 53 years. Medications recorded were then matched to a British
National Formulary (BNF) code
(British Medical Association & Royal
Pharmaceutical Society of Great Britain, 2002) by a trained
research nurse. Medications described in this report are those used for
treatment of common psychiatric symptoms: hypnotics (BNF section
4.1.1), anxiolytics (BNF section 4.1.2) and antidepressants
(BNF section 4.3). In addition, survey members were asked at age 36
years and age 43 years if they had visited a physician in the previous year
for `nerves'.
Definitions
Throughout this paper we use the term `common mental disorder' to describe
cases of mental disorder characterised by symptoms of depression and/or
anxiety (Goldberg, 1991).
Common mental disorder
Presence of adult common mental disorder was measured by the Present State
Examination (PSE; Wing et al,
1974) at age 36 years, by the Psychiatric Symptom Frequency scale
(PSF; Lindelow et al,
1997) at age 43 years and by the 28-item General Health
Questionnaire (GHQ; Goldberg & Hillier,
1979) at age 53 years. Survey members were categorised as cases at
age 36 years if they scored 5 or higher on the Index of Definition on the PSE
(Wing et al, 1978),
yielding a prevalence of 6%. Survey members were categorised as cases if they
scored in the most severely affected 6% on the PSF and GHQ at ages 43 and 53
years respectively.
Statistical method
Prevalence of reported use of antidepressants, anxiolytics and hypnotics at
ages 31, 36, 43 and 53 years is presented as crude data and as number of
individuals per 1000 persons in the survey population. The trend in prevalence
over these four ages was analysed using a chi-squared test for trend.
Prevalence of antidepressant, anxiolytic or hypnotic use among those with
common mental disorder is presented as a proportion, and associations between
medication use and common mental disorder are presented using odds ratios and
95% confidence intervals. The association between severity of symptoms of
common mental disorder and prevalence of antidepressant, anxiolytic or
hypnotic use was analysed using a chi-squared test for trend. Prevalence of
antidepressant, anxiolytic or hypnotic use and associations between medication
use and common mental disorder over time are presented with proportions, ORs
and 95% CIs. The focus of our analysis was common mental disorders, so we
eliminated individuals who reported use of antipsychotics (BNF
sections 4.2.1 and 4.2.2) or mood stabilisers (antimanic drugs; BNF
section 4.2.3) at any time during the follow-up period (n=55). All
analyses were performed using Stata version 8.0 for Windows.
|
|
RESULTS |
|---|
|
|
|---|
2 test for trend,
P<0.001), as the cohort aged
(Table 1). Prevalence of
individuals using more than one class of psychotropic medication was low: 5.4
per 1000 in 1977, 4.3 per 1000 in 1982, 4.7 per 1000 in 1989, to 7.1 per 1000
in 1999.
|
Use of specific classes of medications in 1977 (age 31), 1982 (age 36), 1989 (age 43) and 1999 (age 53) is shown in Table 1. Use of anxiolytic medications dropped from 1977 to 1999, whereas antidepressant use, in contrast, increased. With regard to specific medications, the most common drug in 1977, 1982 and 1989 was diazepam (13.9, 16.5 and 12.8 per 1000 respectively). In 1999 the most common medication was the tricyclic antidepressant amitriptyline (10.9 per 1000), followed by the selective serotonin reuptake inhibitor fluoxetine (9.2 per 1000).
Associations between antidepressant, anxiolytic or hypnotic use and common mental disorder
Table 2 shows the prevalence
of antidepressant, anxiolytic or hypnotic use among individuals with and
without common mental disorder at ages 36, 43 and 53 years. Prevalence of
medication use among those with such disorder was relatively constant: 23.3%
at age 36, 27.0% at age 43 and 27.0% at age 53. Those identified as having a
common mental disorder were significantly more likely to be using these
psychotropic medications than those below the cut-off for such disorder, with
OR in the range 7.7-11.9 (Table
2).
|
Among those using an antidepressant, anxiolytic or hypnotic, only 30.6%
were identified as having a common mental disorder at age 36, 37.5% at age 43
and 27.2% at age 53 years. Figure
1 shows that those using an antidepressant, anxiolytic or hypnotic
who did not reach the threshold for common mental disorder might have been
experiencing sub-threshold or partially treated symptoms. A significant trend
can be seen between severity of symptoms and prevalence of medication use at
ages 36, 43 and 53 years (
2 test for trend;
P<0.001 for all three ages).
|
Antidepressant, anxiolytic and hypnotic use over time
Investigation of medication use over time revealed that previous use of
antidepressants, anxiolytics or hypnotics was a strong predictor of future use
(Table 3). Individuals who used
such medications at age 31 were 14.5 times more likely to use them at age 36
than those not using these drugs at age 31. Similar associations could be seen
from age 36 to age 43, and from age 43 to age 53. Longer-term associations
were also evident - individuals who used antidepressants, anxiolytics or
hypnotics at age 31 were 9.8 times more likely to use these medications at age
53 than those not using them at age 31.
|
During an episode of common mental disorder, individuals were more likely to use antidepressants, anxiolytics or hypnotics if they had used such medications in the past (Table 4). Individuals at age 36, for example, were 8.6 times more likely to use antidepressants, anxiolytics or hypnotics during an episode of common mental disorder if they had used these drugs at age 31. Similar results were observed for those with common mental disorder at ages 43 and 53, although the effect was less pronounced at each subsequent age. It is notable that the proportion of individuals who had used antidepressants, anxiolytics or hypnotics in the past and continued to use them in a subsequent episode of common mental disorder dropped as the cohort aged. For example, only 40.0% of individuals who had previously used an antidepressant, anxiolytic or hypnotic chose this treatment during an episode of common mental disorder at age 53.
|
|
|
DISCUSSION |
|---|
|
|
|---|
Mental disorder and use of antidepressants, anxiolytics and hypnotics
The associations between mental disorder among members of the NSHD and
psychiatric treatment are notable. At ages 36 and 43, less than half of those
with common mental disorder had visited a physician for treatment for nerves
in the previous year. Less than a third of individuals with common mental
disorder were using a psychotropic medication at ages 36, 43 and 53. These
results mirror studies from numerous countries that show that less than half
of individuals with common mental disorder seek physician treatment
(Howard et al, 1996;
Lefebvre et al, 1998;
Andrews et al, 2001;
Spijker et al, 2001;
Bebbington et al,
2003; Burns et al,
2003), and less than 40% use psychotropic medications
(Spijker et al, 2001;
Bebbington et al,
2003; Simon et al,
2004; Patten et al,
2005).
It is less clear why the majority of individuals with evidence of common mental disorder are not treated for it. There is a strong body of evidence suggesting that an important factor is patient perception of the need for help. In the National Comorbidity Survey in the USA, only 34% of 1792 individuals with mood and/or anxiety disorders perceived a need for professional help (Mojtabai et al, 2002). Regardless of reasons that influence the decision to seek care, it appears that Goldberg & Huxley's seminal model of the pathway to psychiatric care (Goldberg & Huxley, 1980) remains pertinent: it is only a fraction of individuals with common mental disorders who seek help, a smaller fraction have their disorder recognised by their physician, and a yet smaller fraction receive appropriate care.
It is notable that the majority of individuals using a psychotropic medication do not reach the threshold for common mental disorder. Similar results have recently been reported in a Canadian study (Patten et al, 2005). Without data describing the course of their illness, it is unclear whether these are patients whose symptoms have recently subsided, patients who are on successful maintenance therapy, or patients who are being treated more aggressively than may be necessary. Our results, however, showing a strong association between severity of symptoms and likelihood of treatment with psychotropic medication suggest that individuals who do not meet the threshold for common mental disorder but are using psychotropic medications are probably experiencing sub-threshold symptoms and their treatment may be appropriate.
Individual use of antidepressants, anxiolytics and hypnotics over time
Presenting data from 1977 to 1999 gives a unique perspective on
individuals' use of psychotropic medications over time. Psychotropic
medication use at any time was strongly predictive of future use, even 22
years later. In addition, as retrospective studies have suggested
(Blumenthal & Endicott,
1996; Burns et al,
2003), previous use of psychotropic medication is a strong
predictor of whether individuals would seek pharmaceutical treatment during a
future episode of mental disorder. It was notable, however, that this
association became weaker as the cohort aged. Not using a treatment during an
episode of mental disorder that had been previously employed may indicate a
treatment failure in the past. Individuals may be requesting
non-pharmaceutical treatments such as cognitive-behavioural therapy, or simply
not seeking treatment at all.
Limitations and strengths of the study
One limitation of our study is that we do not have information on
non-pharmaceutical treatment of mental disorder among the survey members. The
fact that approximately 40-50% of individuals in our investigation who had a
common mental disorder and saw a physician for `nerves' in the past year were
not taking psychotropic medication suggests that some might have been treated
with psychotherapy or other non-pharmacological approaches. Results from a
British study show that psychotherapeutic treatment is almost as common as
treatment with psychotropic medication among individuals with a neurotic
mental disorder who consulted a primary care physician in the previous year
(Bebbington et al,
2003), and similar results have been reported in the USA
(Olfson et al, 2002).
There is evidence to support some psychotherapeutic approaches, such as
cognitive-behavioural therapy, as an alternative or adjunct to pharmacotherapy
for depression (DeRubeis et al,
1999,
2005), so it is possible that
the proportion of individuals who are receiving appropriate treatment for
their mental disorder is higher than the proportions using psychotropic
medication reported here. In addition, it is worth noting that the majority of
cases of depression remit without any form of psychiatric treatment
(Wells et al,
1992).
Another limitation of this study is that we do not measure distinct DSM disorders separately. Given the comorbidity between many DSM mental disorders (Kessler et al, 1994), we do not expect this to affect our results significantly. Evidence suggests, for example, that mixed and/or comorbid anxiety and depression are more common than either disorder alone (Singleton et al, 2003), symptoms of anxiety are frequently successfully treated with selective serotonin reuptake inhibitor antidepressants (Kapczinski et al, 2003) and individuals with numerous anxiety and depressive disorders have increased use of antidepressants, anxiolytics and hypnotics (Bebbington et al, 2003; Ohayon & Lader, 2002). Furthermore, all classes of psychotropic medications (antidepressants, anxiolytics and hypnotics) in our study were significantly associated with our measure of common mental disorder (further information available from the authors upon request).
A final limitation is that we did not know the stage of illness of the participants with mental disorder. It is possible that individuals who had not sought treatment were at an early phase of their mental illness and would have sought treatment as the illness continued. All comparable studies in this area face this limitation, the only solution being an intensive prospective study of the onset of illness and whether individuals subsequently seek treatment.
The study design of the NSHD also offers some notable methodological strengths. This survey has a large sample that is population-based, with all data being prospectively collected over a 53-year period. This has allowed us to present data on population trends of antidepressant, anxiolytic and hypnotic use, associations between antidepressant, anxiolytic and hypnotic use and common mental disorder, and trends in individual use of these medications over time. These results confirm that although psychotropic medication use is rising, the majority of individuals with an identifiable common mental disorder are not being treated with drugs.
|
|
ACKNOWLEDGMENTS |
|---|
|
|
|---|
|
|
REFERENCES |
|---|
|
|
|---|
Bebbington, P., Brugha, T., Meltzer, H., et al (2003) Neurotic disorders and the receipt of psychiatric treatment. International Review of Psychiatry, 15, 108 -114.[CrossRef][Medline]
Blumenthal, R. & Endicott, J. (1996) Barriers to seeking treatment for major depression. Depression and Anxiety, 4, 273 -278.[CrossRef][Medline]
British Medical Association & Royal Pharmaceutical Society of Great Britain (2002) British National Formulary (September issue). London & Wallingford: BMJ Books & Pharmaceutical Press.
Burns, T., Eichenberger, A., Eich, D., et al (2003) Which individuals with affective symptoms seek help? Results from the Zurich epidemiological study. Acta Psychiatrica Scandinavica, 108, 419 -426.[CrossRef][Medline]
DeRubeis, R. J., Gelfand, L. A., Tang, T. Z., et al
(1999)(1999) Medications versus cognitive behavior therapy
for severely depressed outpatients: mega-analysis of four randomized
comparisons. American Journal of Psychiatry,
156, 1007
-1013.
DeRubeis, R. J., Hollon, S.D., Amsterdam, J. D., et al
(2005) Cognitive therapy vs medications in the treatment of
moderate to severe depression. Archives of General
Psychiatry, 62, 409
-416.
Goldberg, D. (1991) Common Mental Disorders: A Biosocial Model. London: Routledge.
Goldberg, D. P. & Hillier, V. F. (1979) A scaled version of the General Health Questionnaire. Psychological Medicine, 9, 139 -145.[Medline]
Goldberg, D. & Huxley, P. (1980) Mental Illness in the Community: The Pathway to Psychiatric Care. London: Tavistock.
Helgason, T., Tómasson, H. & Zoega, T.
(2004) Antidepressants and public health in Iceland. Time
series analysis of national data. British Journal of
Psychiatry, 184, 157
-162.
Howard, K. I., Cornille, T. A., Lyons, J. S., et al (1996) Patterns of mental health service utilization. Archives of General Psychiatry, 53, 696 -703.[Abstract]
Kapczinski, F., Lima, M. S., SouzaSouza,, J. S., et al (2003) Antidepressants for generalized anxiety disorder. Cochrane Database of Systematic Reviews, issue 2. Oxford: Update Software.
Kessler, R. C., McGonagle, K. A., Zhao, S., et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 51, 8-19.[Abstract]
Lefebvre, J., Lesage, A., Cyr, M., et al (1998) Factors related to utilization of services for mental health reasons in Montreal, Canada. Social Psychiatry and Psychiatric Epidemiology, 33, 291 -298.[CrossRef][Medline]
Lindelow, M., Hardy, R. & Rodgers, B. (1997) Development of a scale to measure symptoms of anxiety and depression in the general UK population: the psychiatric symptom frequency scale. Journal of Epidemiology and Community Health, 51, 549 -557.[Abstract]
Middleton, N., Gunnell, D., Whitley, E., et al
(2001) Secular trends in antidepressant prescribing in the
UK, 1975-1998.Journal of Public Health Medicine,
23, 262
-267.
Mojtabai, R., Olfson, M. & Mechanic, D.
(2002) Perceived need and help-seeking in adults with mood,
anxiety, or substance use disorders. Archives of General
Psychiatry, 59, 77
-84.
Ohayon, M. M. & Lader, M. H. (2002) Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Journal of Clinical Psychiatry, 63, 817 -825.[Medline]
Olfson, M., Marcus, S. C., Druss, B., et al
(2002) National trends in the outpatient treatment of
depression. JAMA, 287, 203
-209.
Patten, S. B., Williams, J. V., Wang, J., et al (2005) Antidepressant pharmacoepidemiology in a general population sample. Journal of Clinical Psychopharmacology, 25, 285 -287.[CrossRef][Medline]
Paykel, E. S., Hart, D. & Priest, R. G.
(1998) Changes in public attitudes to depression during the
Defeat Depression Campaign. British Journal of
Psychiatry, 173, 519
-522.
Simon, G. E., Fleck, M., Lucas, R., et al
(2004) Prevalence and predictors of depression treatment in
an international primary care study. American Journal of
Psychiatry, 161, 1626
-1634.
Singleton, N., Bumpstead, R., O'Brien, M., et al (2003) Psychiatric morbidity among adults living in private households, 2000. International Review of Psychiatry, 15, 65-73.[CrossRef][Medline]
Spijker, J., Bijl, R. V., de Graaf, R., et al (2001) Care utilization and outcome of DSM-III-R major depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatrica Scandinavica, 104, 19 -24.[CrossRef][Medline]
Wadsworth, M. E. J. (1991) The Imprint of Time. Oxford: Oxford University Press.
Wadsworth, M. E., Mann, S. L., Rodgers, B., et al (1992) Loss and representativeness in a 43 year follow up of a national birth cohort. Journal of Epidemiology and Community Health, 46, 300 -304.[Abstract]
Wadsworth, M. E., Butterworth, S. L., Hardy, R. J., et al (2003) The life course prospective design: an example of benefits and problems associated with study longevity. Social Science and Medicine, 57, 2193 -2205.[CrossRef]
Wells, K. B., Burnam, M. A., Rogers, W., et al (1992) The course of depression in adult outpatients. Results from the Medical Outcomes Study. Archives of General Psychiatry, 49, 788 -794.[Abstract]
Wing, J. K., Cooper, J. E. & Sartorius, N. (1974) The Measurement and Classification of Psychiatric Symptoms. Cambridge: Cambridge University Press.
Wing, J. K., Mann, S. A., Leff, J. P., et al (1978) The concept of a `case' in psychiatric population surveys. Psychological Medicine, 8, 203-217.[Medline]
Received for publication September 26, 2005. Revision received February 1, 2006. Accepted for publication March 3, 2006.
Related articles in BJP:
This article has been cited by other articles:
![]() |
I. Colman, T. J. Croudace, M. E. J. Wadsworth, D. Kuh, and P. B. Jones Psychiatric outcomes 10 years after treatment with antidepressants or anxiolytics The British Journal of Psychiatry, October 1, 2008; 193(4): 327 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tyrer From the Editor's desk The British Journal of Psychiatry, May 1, 2008; 192(5): 400 - 400. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |